Back to search

Peptide record

TPDB07300

LL-37(17-29) Antibacterial Anticancer Antifungal Antiparasitic Antiviral Cell-penetrating Peptides Toxicity standard
13 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB07300
LL-37(17-29)
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Cell-penetrating Peptides Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
AntiBP3 dbAMP DRAMP Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF CAFPdb AI4AVP dbAMP 3.0 DRAVP 2.0 CPPsite3.0
standard
No
A 13-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
FKRIVQRIKDFLR
Physicochemical Analysis
C80H135N25O17
ANCEGHMPSTWY
R
1719.11
12.13
5
1
6
+4
2.85
-0.438
112.31
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
1
Residue Composition
number
0
A
3
R
0
N
1
D
0
C
0
E
1
Q
0
G
0
H
2
I
1
L
2
K
0
M
2
F
0
P
0
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 0 R: 3 N: 0 D: 1 C: 0 E: 0 Q: 1 G: 0 H: 0 I: 2 L: 1 K: 2 M: 0 F: 2 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
13
C80H135N25O17
1719.11
12.13
+4
2.85
-0.438
Free
L
Linear
Free
Antibacterial
LL-37,a series of peptide fragments
Evidence Records 38 records
Evidence 1 Activity

Activity

MIC
Antibacterial
16 µM

Target

Escherichia coli KCTC 1682

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Active against E. coli KCTC 1682 (MIC 16 uM), P. aeruginosa KCTC 1637 (MIC 32 uM), S. typhimurium KCTC 1926 (MIC 16 uM), Gram+ B. subt
Evidence 2 Activity

Activity

MIC
Antibacterial
32 µM

Target

Pseudomonas aeruginosa KCTC 1637

Source & Reference

dbAMP DRAMP

Other

Active against E. coli KCTC 1682 (MIC 16 uM), P. aeruginosa KCTC 1637 (MIC 32 uM), S. typhimurium KCTC 1926 (MIC 16 uM), Gram+ B. subtilis KCTC 3068 (MIC 4 uM), S. epiderm
Evidence 3 Activity

Activity

MIC
Antibacterial
16 µM

Target

S. typhimurium KCTC 1926

Source & Reference

dbAMP DRAMP

Other

Active against E. coli KCTC 1682 (MIC 16 uM), P. aeruginosa KCTC 1637 (MIC 32 uM), S. typhimurium KCTC 1926 (MIC 16 uM), Gram+ B. subtilis KCTC 3068 (MIC 4 uM), S. epidermidis KCTC 1917 (MIC 16 uM), and S. aur
Evidence 4 Activity

Activity

MIC
Antibacterial
4 µM

Target

B. subtilis KCTC 3068

Source & Reference

dbAMP DRAMP

Other

16 uM), P. aeruginosa KCTC 1637 (MIC 32 uM), S. typhimurium KCTC 1926 (MIC 16 uM), Gram+ B. subtilis KCTC 3068 (MIC 4 uM), S. epidermidis KCTC 1917 (MIC 16 uM), and S. aureus KCTC1621 (MIC 16 uM) ( Rajasekaran e
Evidence 5 Activity

Activity

MIC
Antibacterial
16 µM

Target

Staphylococcus epidermidis KCTC 1917

Source & Reference

dbAMP DRAMP

Other

MIC 32 uM), S. typhimurium KCTC 1926 (MIC 16 uM), Gram+ B. subtilis KCTC 3068 (MIC 4 uM), S. epidermidis KCTC 1917 (MIC 16 uM), and S. aureus KCTC1621 (MIC 16 uM) ( Rajasekaran et al., 2017 ). Also S. hominis (MIC 39
Evidence 6 Activity

Activity

MIC
Antibacterial
16 µM

Target

Staphylococcus aureus KCTC1621

Source & Reference

dbAMP DRAMP

Other

16 uM), Gram+ B. subtilis KCTC 3068 (MIC 4 uM), S. epidermidis KCTC 1917 (MIC 16 uM), and S. aureus KCTC1621 (MIC 16 uM) ( Rajasekaran et al., 2017 ). Also S. hominis (MIC 39 uM) (See AP4772). Virus: inhibited
Evidence 7 Activity

Activity

MIC
Antibacterial
39 µM

Target

Staphylococcus hominis

Source & Reference

dbAMP DRAMP

Other

C 1917 (MIC 16 uM), and S. aureus KCTC1621 (MIC 16 uM) ( Rajasekaran et al., 2017 ). Also S. hominis (MIC 39 uM) (See AP4772). Virus: inhibited Human Immunodeficiency Virus Type 1 HIV-1 (EC50 3.4 uM, TC
Evidence 8 Activity

Activity

LC50
LC50=60 µM
Anticancer
60 µM

Target

Tumor
KBv
Not Available

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 9 Activity

Activity

LC50
LC50=57 µM
Anticancer
57 µM

Target

Oral Cancer
KB
Not Available

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 10 Activity

Activity

LC50
LC50=55 µM
Anticancer
55 µM

Target

Prostate Cancer
HBMEC
Not Available

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2006
Evidence 11 Activity

Activity

MIC
Antifungal
16 µM

Target

Escherichia coli KCTC 1682

Source & Reference

dbAMP DRAMP CAFPdb

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Active against E. coli KCTC 1682 (MIC 16 uM), P. aeruginosa KCTC 1637 (MIC 32 uM), S. typhimurium KCTC 1926 (MIC 16 uM), Gram+ B. subt
Evidence 12 Activity

Activity

MIC
Antifungal
32 µM

Target

Pseudomonas aeruginosa KCTC 1637

Source & Reference

dbAMP DRAMP CAFPdb

Other

Active against E. coli KCTC 1682 (MIC 16 uM), P. aeruginosa KCTC 1637 (MIC 32 uM), S. typhimurium KCTC 1926 (MIC 16 uM), Gram+ B. subtilis KCTC 3068 (MIC 4 uM), S. epiderm
Evidence 13 Activity

Activity

MIC
Antifungal
16 µM

Target

S. typhimurium KCTC 1926

Source & Reference

dbAMP DRAMP CAFPdb

Other

Active against E. coli KCTC 1682 (MIC 16 uM), P. aeruginosa KCTC 1637 (MIC 32 uM), S. typhimurium KCTC 1926 (MIC 16 uM), Gram+ B. subtilis KCTC 3068 (MIC 4 uM), S. epidermidis KCTC 1917 (MIC 16 uM), and S. aur
Evidence 14 Activity

Activity

MIC
Antifungal
4 µM

Target

B. subtilis KCTC 3068

Source & Reference

dbAMP DRAMP CAFPdb

Other

16 uM), P. aeruginosa KCTC 1637 (MIC 32 uM), S. typhimurium KCTC 1926 (MIC 16 uM), Gram+ B. subtilis KCTC 3068 (MIC 4 uM), S. epidermidis KCTC 1917 (MIC 16 uM), and S. aureus KCTC1621 (MIC 16 uM) ( Rajasekaran e
Evidence 15 Activity

Activity

MIC
Antifungal
16 µM

Target

Staphylococcus epidermidis KCTC 1917

Source & Reference

dbAMP DRAMP CAFPdb

Other

MIC 32 uM), S. typhimurium KCTC 1926 (MIC 16 uM), Gram+ B. subtilis KCTC 3068 (MIC 4 uM), S. epidermidis KCTC 1917 (MIC 16 uM), and S. aureus KCTC1621 (MIC 16 uM) ( Rajasekaran et al., 2017 ). Also S. hominis (MIC 39
Evidence 16 Activity

Activity

MIC
Antifungal
16 µM

Target

Staphylococcus aureus KCTC1621

Source & Reference

dbAMP DRAMP CAFPdb

Other

16 uM), Gram+ B. subtilis KCTC 3068 (MIC 4 uM), S. epidermidis KCTC 1917 (MIC 16 uM), and S. aureus KCTC1621 (MIC 16 uM) ( Rajasekaran et al., 2017 ). Also S. hominis (MIC 39 uM) (See AP4772). Virus: inhibited
Evidence 17 Activity

Activity

MIC
Antifungal
39 µM

Target

Staphylococcus hominis

Source & Reference

dbAMP DRAMP CAFPdb

Other

C 1917 (MIC 16 uM), and S. aureus KCTC1621 (MIC 16 uM) ( Rajasekaran et al., 2017 ). Also S. hominis (MIC 39 uM) (See AP4772). Virus: inhibited Human Immunodeficiency Virus Type 1 HIV-1 (EC50 3.4 uM, TC
Evidence 18 Activity

Activity

MIC
Antiparasitic
16 µM

Target

Escherichia coli KCTC 1682

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets. dbAMP 3.0 classified under the Anti-parasitic function class.
Active against E. coli KCTC 1682 (MIC 16 uM), P. aeruginosa KCTC 1637 (MIC 32 uM), S. typhimurium KCTC 1926 (MIC 16 uM), Gram+ B. subt
Evidence 19 Activity

Activity

MIC
Antiparasitic
32 µM

Target

Pseudomonas aeruginosa KCTC 1637

Source & Reference

dbAMP 3.0 DRAMP

Other

Active against E. coli KCTC 1682 (MIC 16 uM), P. aeruginosa KCTC 1637 (MIC 32 uM), S. typhimurium KCTC 1926 (MIC 16 uM), Gram+ B. subtilis KCTC 3068 (MIC 4 uM), S. epiderm
Evidence 20 Activity

Activity

MIC
Antiparasitic
16 µM

Target

S. typhimurium KCTC 1926

Source & Reference

dbAMP 3.0 DRAMP

Other

Active against E. coli KCTC 1682 (MIC 16 uM), P. aeruginosa KCTC 1637 (MIC 32 uM), S. typhimurium KCTC 1926 (MIC 16 uM), Gram+ B. subtilis KCTC 3068 (MIC 4 uM), S. epidermidis KCTC 1917 (MIC 16 uM), and S. aur
Evidence 21 Activity

Activity

MIC
Antiparasitic
4 µM

Target

B. subtilis KCTC 3068

Source & Reference

dbAMP 3.0 DRAMP

Other

16 uM), P. aeruginosa KCTC 1637 (MIC 32 uM), S. typhimurium KCTC 1926 (MIC 16 uM), Gram+ B. subtilis KCTC 3068 (MIC 4 uM), S. epidermidis KCTC 1917 (MIC 16 uM), and S. aureus KCTC1621 (MIC 16 uM) ( Rajasekaran e
Evidence 22 Activity

Activity

MIC
Antiparasitic
16 µM

Target

Staphylococcus epidermidis KCTC 1917

Source & Reference

dbAMP 3.0 DRAMP

Other

MIC 32 uM), S. typhimurium KCTC 1926 (MIC 16 uM), Gram+ B. subtilis KCTC 3068 (MIC 4 uM), S. epidermidis KCTC 1917 (MIC 16 uM), and S. aureus KCTC1621 (MIC 16 uM) ( Rajasekaran et al., 2017 ). Also S. hominis (MIC 39
Evidence 23 Activity

Activity

MIC
Antiparasitic
16 µM

Target

Staphylococcus aureus KCTC1621

Source & Reference

dbAMP 3.0 DRAMP

Other

16 uM), Gram+ B. subtilis KCTC 3068 (MIC 4 uM), S. epidermidis KCTC 1917 (MIC 16 uM), and S. aureus KCTC1621 (MIC 16 uM) ( Rajasekaran et al., 2017 ). Also S. hominis (MIC 39 uM) (See AP4772). Virus: inhibited
Evidence 24 Activity

Activity

MIC
Antiparasitic
39 µM

Target

Staphylococcus hominis

Source & Reference

dbAMP 3.0 DRAMP

Other

C 1917 (MIC 16 uM), and S. aureus KCTC1621 (MIC 16 uM) ( Rajasekaran et al., 2017 ). Also S. hominis (MIC 39 uM) (See AP4772). Virus: inhibited Human Immunodeficiency Virus Type 1 HIV-1 (EC50 3.4 uM, TC
Evidence 25 Activity

Activity

MIC
Antiviral
16 µM

Target

Escherichia coli KCTC 1682

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets. dbAMP 3.0 classified under the Anti-viral function class.
Active against E. coli KCTC 1682 (MIC 16 uM), P. aeruginosa KCTC 1637 (MIC 32 uM), S. typhimurium KCTC 1926 (MIC 16 uM), Gram+ B. subt
Evidence 26 Activity

Activity

MIC
Antiviral
32 µM

Target

Pseudomonas aeruginosa KCTC 1637

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Active against E. coli KCTC 1682 (MIC 16 uM), P. aeruginosa KCTC 1637 (MIC 32 uM), S. typhimurium KCTC 1926 (MIC 16 uM), Gram+ B. subtilis KCTC 3068 (MIC 4 uM), S. epiderm
Evidence 27 Activity

Activity

MIC
Antiviral
16 µM

Target

S. typhimurium KCTC 1926

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Active against E. coli KCTC 1682 (MIC 16 uM), P. aeruginosa KCTC 1637 (MIC 32 uM), S. typhimurium KCTC 1926 (MIC 16 uM), Gram+ B. subtilis KCTC 3068 (MIC 4 uM), S. epidermidis KCTC 1917 (MIC 16 uM), and S. aur
Evidence 28 Activity

Activity

MIC
Antiviral
4 µM

Target

B. subtilis KCTC 3068

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

16 uM), P. aeruginosa KCTC 1637 (MIC 32 uM), S. typhimurium KCTC 1926 (MIC 16 uM), Gram+ B. subtilis KCTC 3068 (MIC 4 uM), S. epidermidis KCTC 1917 (MIC 16 uM), and S. aureus KCTC1621 (MIC 16 uM) ( Rajasekaran e
Evidence 29 Activity

Activity

MIC
Antiviral
16 µM

Target

Staphylococcus epidermidis KCTC 1917

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

MIC 32 uM), S. typhimurium KCTC 1926 (MIC 16 uM), Gram+ B. subtilis KCTC 3068 (MIC 4 uM), S. epidermidis KCTC 1917 (MIC 16 uM), and S. aureus KCTC1621 (MIC 16 uM) ( Rajasekaran et al., 2017 ). Also S. hominis (MIC 39
Evidence 30 Activity

Activity

MIC
Antiviral
16 µM

Target

Staphylococcus aureus KCTC1621

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

16 uM), Gram+ B. subtilis KCTC 3068 (MIC 4 uM), S. epidermidis KCTC 1917 (MIC 16 uM), and S. aureus KCTC1621 (MIC 16 uM) ( Rajasekaran et al., 2017 ). Also S. hominis (MIC 39 uM) (See AP4772). Virus: inhibited
Evidence 31 Activity

Activity

MIC
Antiviral
39 µM

Target

Staphylococcus hominis

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

C 1917 (MIC 16 uM), and S. aureus KCTC1621 (MIC 16 uM) ( Rajasekaran et al., 2017 ). Also S. hominis (MIC 39 uM) (See AP4772). Virus: inhibited Human Immunodeficiency Virus Type 1 HIV-1 (EC50 3.4 uM, TC
Evidence 32 Activity

Activity

50% cell death
Toxicity
10.4 µM
Cytotoxic
50% cell death | 10.4 | µM | target cell: CEM-SS cells

Target

CEM-SS cells

Source & Reference

NA
DBAASP
Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins | Antimicrob Agents Chemother | 2008
Evidence 33 Activity

Activity

EC50
Toxicity
>200 µg/mL
Cytotoxic
EC50 | >200 | µg/mL | target cell: Human corneal epithelial cells HCE-2

Target

Human corneal epithelial cells HCE-2

Source & Reference

NA
DBAASP
Cathelicidin-Derived Synthetic Peptide Improves Therapeutic Potential of Vancomycin Against Pseudomonas aeruginosa. | Front Microbiol | 2019
Evidence 34 Activity

Activity

10% Hemolysis
Toxicity
160 µM
Hemolytic Cytotoxic
10% Hemolysis | 160 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Disruption of interactions between hydrophobic residues on nonpolar faces is a key determinant in decreasing hemolysis and increasing antimicrobial activities of α-helical amphipathic peptides. | ChemMedChem | 2013
Evidence 35 Activity

Activity

50% Cell death
Toxicity
55±2 µM
Cytotoxic
50% Cell death | 55±2 | µM | target cell: Human brain microvascular endothelial cells HBMEC

Target

Human brain microvascular endothelial cells HBMEC

Source & Reference

NA
DBAASP
Solution structures of human LL-37 fragments and NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region. | J Am Chem Soc | 2006
Evidence 36 Activity

Activity

50% Hemolysis
Toxicity
>256 µM
Hemolytic Cytotoxic
50% Hemolysis | >256 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
LL-37-derived membrane-active FK-13 analogs possessing cell selectivity, anti-biofilm activity and synergy with chloramphenicol and anti-inflammatory activity. | Biochim Biophys Acta | 2017
Evidence 37 Activity

Activity

IC50
Toxicity
29.3 µg/mL
Cytotoxic
IC50 | 29.3 | µg/mL | target cell: Human Lung Fibroblasts

Target

Human Lung Fibroblasts

Source & Reference

NA
DBAASP
Cationic amphipathic peptide analogs of cathelicidin LL-37 as a probe in the development of antimicrobial/anticancer agents. | J Pept Sci | 2020
Evidence 38 Activity

Activity

HC50
Toxicity
256 µM
Hemolytic
Hemolytic_activity: [Ref.28161291] HC50>256 µM against human red blood cells. [Ref.23894079] MHC10=160 µM against human red blood cells

Target

erythrocytes

Source & Reference

NA
DRAMP
J Am Chem Soc. 2006 May 3 128(17):5776-5785.##Int J Mol Sci. 2017 Feb 6 18(2). pii: E339. ##Biochim Biophys Acta Biomembr. 2017 May 1859(5):722-733.##ChemMedChem. 2013 Oct 8(10):1638-42.